PubMed日本語 - 自然に感染した集団のHPV16血清陽性と以降のHPV16感染リスク:血清学的分析の比較。―QLifePro医療翻訳医療翻訳 QLifePro


HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays.


Published date



Shih-Wen Lin, Arpita Ghosh, Carolina Porras, Sarah C Markt, Ana Cecilia Rodriguez, Mark Schiffman, Sholom Wacholder, Troy J Kemp, Ligia A Pinto, Paula Gonzalez, Nicolas Wentzensen, Mark T Esser, Katie Matys, Ariane Meuree, Wim Quint, Leen-Jan van Doorn, Rolando Herrero, Allan Hildesheim, Mahboobeh Safaeian,


Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America.


BACKGROUND: Several serological assays have been developed to detect antibodies elicited against infections with oncogenic human papillomavirus (HPV) type 16. The association between antibody levels measured by various assays and subsequent HPV infection risk may differ. We compared HPV16-specific antibody levels previously measured by a virus-like particle (VLP)-based direct enzyme-linked immunoassay (ELISA) with levels measured by additional assays and evaluated the protection against HPV16 infection conferred at different levels of the assays.


METHODOLOGY/PRINCIPAL FINDINGS: Replicate enrollment serum aliquots from 388 unvaccinated women in the control arm of the Costa Rica HPV vaccine trial were measured for HPV16 seropositivity using three serological assays: a VLP-based direct ELISA; a VLP-based competitive Luminex immunoassay (cLIA); and a secreted alkaline phosphatase protein neutralization assay (SEAP-NA). We assessed the association of assay seropositivity and risk of subsequent HPV16 infection over four years of follow-up by calculating sampling-adjusted odds ratios (OR) and HPV16 seropositivity based on standard cutoff from the cLIA was significantly associated with protection from subsequent HPV16 infection (OR = 0.48, CI = 0.27-0.86, compared with seronegatives). Compared with seronegatives, the highest seropositive tertile antibody levels from the direct ELISA (OR = 0.53, CI = 0.28-0.90) as well as the SEAP-NA (OR = 0.20, CI = 0.06, 0.64) were also significantly associated with protection from HPV16 infection.


CONCLUSIONS/SIGNIFICANCE: Enrollment HPV16 seropositivity by any of the three serological assays evaluated was associated with protection from subsequent infection, although cutoffs for immune protection were different. We defined the assays and seropositivity levels after natural infection that better measure and translate to protective immunity.



我々は分析血清陽性の関連とサンプリングを調整したオッズ比(OR)を算出することによる4年の追跡調査についての以降のHPV16感染のリスクを評価した、そして、cLIAから標準分離に基づくHPV16血清陽性は以降のHPV16感染(血清否定と比較してOR = 0.48、CI = 0.27-0.86)からの保護と有意に関係していた。
血清否定と比較して、ダイレクトELISA(OR = 0.53、CI = 0.28-0.90)ならびにSEAP-NA(OR = 0.20、CI = 0.06、0.64)から最も高い血清陽性の三分位値抗体レベルは、HPV16感染からの保護とも有意に関係していた。


460万語の専門辞書を備えた医療者専用翻訳サービス QLifePro医療翻訳